{
    "nctId": "NCT03591549",
    "briefTitle": "Fulvestrant in Metastatic Breast Cancer",
    "officialTitle": "Role of Fulvestrant in The Treatment of Metastatic Breast Cancer in Premenopausal Women",
    "overallStatus": "UNKNOWN",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Progression free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women with age 30-50 years old (premenopause).\n* Histological confirmation of metastatic disease.\n* Hormonal receptor positive.\n* Endocrine therapy for early disease had been completed more than 12 months before the study (patients who was not resistance to hormonal therapy).\n* Metastatic breast cancer at presentation.\n* Patients had not received any previous systemic therapy for metastatic disease.\n* Performance status (ECOG) 0-2.\n\nExclusion Criteria:\n\n* Patient \\>55 years old.\n* Non-histologically diagnosed.\n* Hormonal receptor negative\n* Non metastatic\n* received previous line therapy in the metastatic setting.\n* Patient with performance \\>2.\n* Patient with co-morbidity\n* Patients with brain metastasis",
    "sex": "FEMALE",
    "minimumAge": "30 Years",
    "stdAges": "ADULT"
}